| Today's Top Story |  |  | | - Researchers grow partial pituitary gland using stem cells
Japanese researchers used embryonic stem cells to grow partial pituitary glands, then transplanted the tissue in the kidneys of mice without pituitary glands. The transplanted tissue returned hormone levels to normal, according to the study published in Nature. The initiative is part of a worldwide effort to grow complete organs in a lab setting using stem cells. The Guardian (London) (12/4)        | The Business Platinum Card® from American Express OPEN
Spending power for your business. Premium benefits for you.
Access a portfolio of 30+ premium benefits, including:
• Complimentary Airport Club Access
• Annual $200 Airline Fee Credit for any airline
• Built-in upgrades at FINE HOTELS & RESORTS
Business Platinum Card
APPLY NOW |
  - Study finds genetic variation in children with ADHD
At least 10% of children with attention-deficit/hyperactivity disorder showed copy number variations in four glutamate receptor genes, a study found. In a study reported in Nature Genetics, researchers analyzed 1,000 children who have ADHD and 4,100 children without the condition. The study found that ADHD had a genetic basis in some children and offered a potential avenue for developing treatment, an expert said. U.S. News & World Report/HealthDay News (12/4) - Researchers attain functional muscle regeneration in mice
Researchers from the Worcester Polytechnic Institute and CellThera have successfully regenerated functional muscle tissue in mice by growing stem-cell-like human muscle cells on biopolymer microthreads, which were found to help accelerate the process of tissue generation. Findings suggest that "fibrin microthreads alone have tremendous potential for reducing fibrosis and remodeling large muscle injuries," the authors said. Medical News Today (12/1) - Neuroimaging might aid development of Huntington's drugs
Brain-imaging techniques are best for evaluating the progression of Huntington's disease, according to a study in The Lancet Neurology that looked at biomarkers that can improve measurement of disease development. "These methods, coupled with trial designs created to identify and discard unhelpful interventions rapidly, should accelerate the process of finding effective treatments for HD and other neurodegenerative diseases," said the University of Rochester's Karl Kieburtz, who was not part of the study. Medical News Today (12/2)  | Increase Productivity, Reduce R&D Spending
This webinar presents new concepts to improve productivity in the lab and discusses the challenges of implementing new technologies in the organic synthesis lab, their acceptance by chemists, and how a sustainable increase of productivity can be achieved. Register for the webinar. |
 - Icahn's top investor to build his own hedge fund
Alex Denner, considered the top health care investing executive at Carl Icahn, is forming his own hedge fund. Denner, who a source says brought in about $2 billion in profit for Icahn, is known for his ability to identify biotech companies with the potential to produce promising drugs. Some experts in the field say Denner's expertise will give him an advantage in his new venture. Bloomberg Businessweek (12/5) - InVivo Therapeutics readies new headquarters in Mass.
InVivo Therapeutics has signed a six-year lease for a 21,000-square-foot space in Cambridge, Mass., as part of the biotech company's plans to relocate to a new facility early next year. The headquarters will facilitate forthcoming human trials of the company's therapeutic devices for spinal cord injuries, which are awaiting approval from the FDA. Mass High Tech (Boston) (12/2)  | Download the latest Spotlight On… Melanoma report
This quarter’s Spotlight On… report focuses on Melanoma, which is currently experiencing an innovation breakthrough. The Spotlight On... report draws on the expert insight and strategic data from Thomson Reuters Pharma – the world's leading competitive intelligence solution. Download today. |
| Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Some advanced biofuels firms get revenue from specialty chemicals
Several next-generation developers of biofuels are entering the low-volume, high-margin market of specialty chemicals, waiting for the costs of advanced biofuels to go down and technologies to improve, analysts and executives said. "Some people think biochemicals are a crutch on the way to fuels," said Jonathan Wolfson, CEO and co-founder of Solazyme. "We haven't thought about it that way in many, many years." The Wall Street Journal (12/5) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | It is better to use fair means and fail, than foul and conquer."
--Sallust,
Roman historian  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, December 02, 2011
- Thursday, December 01, 2011
- Wednesday, November 30, 2011
- Tuesday, November 29, 2011
- Monday, November 28, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment